ATE413185T1 - Pharmazeutische zusammensetzung zur angiogenese- hemmung mittels eines pedf-fragmentes - Google Patents

Pharmazeutische zusammensetzung zur angiogenese- hemmung mittels eines pedf-fragmentes

Info

Publication number
ATE413185T1
ATE413185T1 AT01914469T AT01914469T ATE413185T1 AT E413185 T1 ATE413185 T1 AT E413185T1 AT 01914469 T AT01914469 T AT 01914469T AT 01914469 T AT01914469 T AT 01914469T AT E413185 T1 ATE413185 T1 AT E413185T1
Authority
AT
Austria
Prior art keywords
pedf
tissue
tumor
growth
provides
Prior art date
Application number
AT01914469T
Other languages
English (en)
Inventor
Noel Bouck
David Dawson
Paul Gillis
Susan Crawford
Veronica Stellmach
Olga Volpert
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/603,478 external-priority patent/US6797691B1/en
Application filed by Univ Northwestern filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE413185T1 publication Critical patent/ATE413185T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01914469T 2000-02-23 2001-02-22 Pharmazeutische zusammensetzung zur angiogenese- hemmung mittels eines pedf-fragmentes ATE413185T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51168300A 2000-02-23 2000-02-23
US09/603,478 US6797691B1 (en) 1997-07-23 2000-06-23 Methods and compositions for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
ATE413185T1 true ATE413185T1 (de) 2008-11-15

Family

ID=27057305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914469T ATE413185T1 (de) 2000-02-23 2001-02-22 Pharmazeutische zusammensetzung zur angiogenese- hemmung mittels eines pedf-fragmentes

Country Status (8)

Country Link
EP (1) EP1265627B1 (de)
JP (1) JP2004516001A (de)
AT (1) ATE413185T1 (de)
AU (1) AU2001239855A1 (de)
CA (1) CA2401096A1 (de)
DE (1) DE60136444D1 (de)
ES (1) ES2316437T3 (de)
WO (1) WO2001062725A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189519A1 (en) * 2002-09-26 2006-08-24 Karl Volz Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)
AU2004285562B2 (en) * 2003-10-29 2011-06-09 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
EP1711172A4 (de) * 2003-12-23 2008-07-16 Univ Pennsylvania Zusammensetzungen und verfahren für die kombinationstherapie von erkrankungen
WO2006046584A1 (ja) * 2004-10-26 2006-05-04 Santen Pharmaceutical Co., Ltd. 視細胞障害治療剤
JP5017535B2 (ja) * 2006-01-23 2012-09-05 株式会社アップウェル 脱毛抑制または発毛促進用組成物
ES2329636B2 (es) * 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) Uso del factor pedf para inducir la auto-renovacion de celulas madre.
AU2009227206A1 (en) 2008-03-18 2009-09-24 Kurume University Polypeptide and pharmaceutical composition containing the polypeptide
EP2486128A4 (de) * 2009-10-08 2013-10-09 Neurotech Usa Inc Verwendung von pedf in einem eingekapselten ausgabesystem auf zellbasis
EP2897976B1 (de) * 2012-09-19 2017-08-09 Mackay Memorial Hospital Verwendung von pedf-abgeleiteten peptiden zur prävention und/oder minderung der hautalterung
US10238722B2 (en) * 2014-11-24 2019-03-26 Ramot At Tel-Aviv University Ltd. Pigment epithelium derived factor (PEDF) for the treatment of uterine fibroids
US10081668B2 (en) 2016-04-26 2018-09-25 Northwestern University Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
KR20230061502A (ko) * 2020-09-03 2023-05-08 큐어바이오텍 게엠베하 황반 변성 또는 맥락막 혈관신생 치료에 사용하기 위한 색소 상피-유래 인자(ｐｅｄｆ)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662087B1 (de) * 1992-06-04 2003-10-01 The University Of Southern California Verfahren zur reinigung eines neurotrophen faktors aus pigmentiertem retinalen epithelgewebe
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US6288024B1 (en) * 1997-07-23 2001-09-11 Northwestern University Methods and compositions for inhibiting angiogenesis

Also Published As

Publication number Publication date
EP1265627A4 (de) 2003-04-23
CA2401096A1 (en) 2001-08-30
WO2001062725A2 (en) 2001-08-30
AU2001239855A1 (en) 2001-09-03
ES2316437T3 (es) 2009-04-16
EP1265627A2 (de) 2002-12-18
JP2004516001A (ja) 2004-06-03
HK1051327A1 (en) 2003-08-01
DE60136444D1 (de) 2008-12-18
WO2001062725A3 (en) 2002-03-21
EP1265627B1 (de) 2008-11-05

Similar Documents

Publication Publication Date Title
ATE413185T1 (de) Pharmazeutische zusammensetzung zur angiogenese- hemmung mittels eines pedf-fragmentes
Boehnke et al. Effects of fibroblasts and microenvironment on epidermal regeneration and tissue function in long-term skin equivalents
Vorotnikova et al. Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo
Liu et al. Pretreatment of mesenchymal stem cells with angiotensin II enhances paracrine effects, angiogenesis, gap junction formation and therapeutic efficacy for myocardial infarction
Liu et al. Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress
Schiera et al. Permeability properties of a three‐cell type in vitro model of blood‐brain barrier
CY1108778T1 (el) Μεθοδος αντιμετωπισης καρκινου του δερματος, χρησιμοποιωντας συνθεσεις οι οποιες περιλαμβανουν εναν αναστολεα του υποδοχεα ενδοθηλινης β
HUP0400371A2 (hu) Szén-monoxid alkalmazása szerv átültetés utáni túlélésének vagy működésének javítására alkalmas gyógyszerkészítmény előállítására
DE60123988D1 (de) Methoden und zubereitungen für die gewebsregeneration
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
Poulin et al. Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens
Sawaya et al. Plasminogen activator activity and molecular weight patterns in human brain tumors
Jiang et al. Cyclic tensile strain promotes the osteogenic differentiation of a bone marrow stromal cell and vascular endothelial cell co-culture system
Litwiniec et al. Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
ATE290789T1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
Imai et al. Oral malodorous compound inhibits osteoblast proliferation
Stirk et al. Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques
Igarashi et al. Construction of large area organotypical cultures of oral mucosa and skin
Speirs et al. Paracrine control of differentiation in the alveolar carcinoma, A549, by human foetal lung fibroblasts
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
TW200515915A (en) Extract of Trapa natans and methods of using the same
Le Sueur et al. In vitro effect of the Phoneutria nigriventer spider venom on cell viability, paracellular barrier function and transcellular transport in cultured cell lines
Sorour et al. Infiltrative potentiality of brain tumors in organ culture

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties